A 10-Day h. pylori cure? new trial tests a streamlined approach

NCT ID NCT07750938

Not yet recruiting Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial compares two ways to eradicate H. pylori, a common stomach infection linked to ulcers and stomach cancer. One group receives a 10-day course of a high-dose acid blocker plus one antibiotic, while the other gets the standard 14-day four-drug regimen. The goal is to see if the shorter, simpler treatment can achieve similar eradication rates with fewer side effects and better adherence. Adults aged 18-70 with a confirmed H. pylori infection and no prior treatment are eligible to participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Keverprazan hydrochloride (a stomach acid blocker) combined with minocycline (an antibiotic), compared to a standard four-drug regimen including bismuth and amoxicillin.
What this could lead to: If successful, this could offer a shorter, simpler, and better-tolerated treatment for H. pylori, potentially improving adherence and reducing side effects while maintaining high cure rates.
What could go wrong: The trial is relatively small and open-label, which may introduce bias. The shorter regimen might not be as effective as the standard one, and the higher acid-blocker dose could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cyclopia sequence Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTIONS

More trials for these conditions

Other studies related to the condition(s) this trial covers.